OCPNF OTC
Olympus Corporation
1W: +1.6%
1M: -9.9%
3M: +21.2%
YTD: -5.1%
1Y: -2.3%
3Y: -8.3%
5Y: -43.4%
$12.13
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
#2
of 13
Medical - Devices
Technical Signal Map
5 Bullish
0 Neutral
20 Bearish
OCPNF
$13B
Olympus Corporation
LEAN BEAR
-27
BIO-B
$10B
Bio-Rad Laboratories, Inc.
BULLISH
+75
BRKR
$9.6B
Bruker Corporation
BULLISH
+66
SONVY
$18B
Sonova Holding AG
BULLISH
+58
WILYY
$9.9B
Demant A/S
BULLISH
+35
HAE
$4.8B
Haemonetics Corporation
BULLISH
+31
TRUMY
$21B
Terumo Corporation
LEAN BEAR
-19
DXCM
$32B
DexCom, Inc.
LEAN BEAR
-25
GMED
$10B
Globus Medical, Inc.
BEARISH
-31
GKOS
$9.7B
Glaukos Corporation
BEARISH
-42
GNGBY
$6.7B
Getinge AB (publ)
BEARISH
-43
SEMHF
$49B
Siemens Healthineers AG
BEARISH
-50
GEHC
$29B
GE HealthCare Technologies Inc.
BEARISH
-58
EW
$49B
Edwards Lifesciences Corporation
BEARISH
-59
PODD
$9.1B
Insulet Corp.
BEARISH
-66
SYK
$106B
Stryker Corporation
BEARISH
-82
MDT
$111B
Medtronic plc
BEARISH
-84
ZBH
$17B
Zimmer Biomet Holdings, Inc.
BEARISH
-84
ABT
$169B
Abbott Laboratories
BEARISH
-87
ALGN
$10B
Align Technology, Inc.
BEARISH
-91
CHEOF
$6.1B
Cochlear Limited
BEARISH
-91
BSX
$63B
Boston Scientific Corporation
BEARISH
-100
PHG
$23B
Koninklijke Philips N.V.
BEARISH
-100
PEN
$13B
Penumbra, Inc.
BEARISH
-100
SNN
$11B
Smith & Nephew plc
BEARISH
-100
Peer Comparison
| Symbol | Mkt Cap | P/E | ROE % | ROIC % | Net Mgn % | Rev Grw % | Piotroski | Signal | 1Y Ret % |
|---|---|---|---|---|---|---|---|---|---|
| OCPNF Olympus Corporation | $13B | 27.5 | 8.7 | 11.6 | 8.4 | 1.5 | 6 | LEAN BEAR | -2.3 |
| BIO-B Bio-Rad Laboratories, Inc. | $10B | 44.3 | 3.1 | 2.2 | 57.1 | 1.4 | 7 | BULLISH | 29.2 |
| BRKR Bruker Corporation | $9.6B | -90.5 | -3.4 | 3.0 | -6.2 | 1.6 | 6 | BULLISH | 82.3 |
| SONVY Sonova Holding AG | $18B | 34.4 | 38.1 | 33.3 | 13.5 | 1.0 | 7 | BULLISH | 10.2 |
| WILYY Demant A/S | $9.9B | 40.7 | 38.1 | 21.5 | 9.1 | 8.7 | 5 | BULLISH | 27.3 |
| HAE Haemonetics Corporation | $4.8B | 50.8 | 12.0 | 10.4 | -5.8 | -2.0 | 6 | BULLISH | 114.5 |
| TRUMY Terumo Corporation | $21B | 20.1 | 9.3 | 8.5 | 8.8 | 10.7 | 4 | LEAN BEAR | -14.0 |
| DXCM DexCom, Inc. | $32B | 33.0 | 38.5 | 42.9 | 19.0 | 15.5 | 9 | LEAN BEAR | 29.2 |
| GMED Globus Medical, Inc. | $10B | 19.0 | 11.8 | 12.3 | 19.2 | 19.7 | 8 | BEARISH | 28.8 |
| GKOS Glaukos Corporation | $9.7B | -50.4 | -26.0 | -12.7 | -9.9 | 41.5 | 3 | BEARISH | 96.9 |
| GNGBY Getinge AB (publ) | $6.7B | 25.1 | 8.9 | 8.0 | 10.0 | -3.9 | 8 | BEARISH | 11.1 |
| SEMHF Siemens Healthineers AG | $49B | 19.1 | 12.1 | 8.4 | 11.6 | 10.0 | 9 | BEARISH | -21.2 |
| GEHC GE HealthCare Technologies Inc. | $29B | 18.5 | 15.4 | 10.6 | 10.8 | 1.4 | 5 | BEARISH | -14.8 |
| EW Edwards Lifesciences Corporation | $49B | 48.9 | 9.5 | 17.9 | 13.9 | 14.6 | 6 | BEARISH | 11.6 |
| PODD Insulet Corp. | $9.1B | 24.6 | 26.0 | 21.3 | 11.8 | 29.4 | 9 | BEARISH | -57.0 |
| SYK Stryker Corporation | $106B | 28.3 | 16.5 | 11.6 | 19.4 | 8.5 | 9 | BEARISH | -24.4 |
| MDT Medtronic plc | $111B | 21.1 | 9.8 | 7.5 | 12.7 | 8.4 | 8 | BEARISH | -8.9 |
| ZBH Zimmer Biomet Holdings, Inc. | $17B | 21.4 | 6.4 | 5.9 | 9.1 | 8.6 | 6 | BEARISH | -10.7 |
| ABT Abbott Laboratories | $169B | 31.4 | 10.7 | 7.3 | 7.4 | 8.1 | 5 | BEARISH | -26.6 |
| ALGN Align Technology, Inc. | $10B | 25.0 | 10.2 | 12.3 | 10.3 | 4.4 | 7 | BEARISH | 12.7 |
| CHEOF Cochlear Limited | $6.1B | 55.7 | 30.0 | 34.3 | -1.2 | 11.5 | 6 | BEARISH | -47.4 |
| BSX Boston Scientific Corporation | $63B | 17.2 | 15.5 | 11.6 | 16.7 | 13.5 | 8 | BEARISH | -55.6 |
| PHG Koninklijke Philips N.V. | $23B | 18.2 | 10.2 | 7.6 | 8.8 | -1.1 | 6 | BEARISH | -13.4 |
| PEN Penumbra, Inc. | $13B | 77.6 | 11.4 | 13.6 | 8.9 | 17.6 | 6 | BEARISH | 27.2 |
| SNN Smith & Nephew plc | $11B | 17.2 | 21.7 | 17.4 | 9.8 | 11.5 | 8 | BEARISH | -27.6 |
| OCPNF Olympus Corporation | $13B | 27.5 | 8.7 | 11.6 | 8.4 | 1.5 | 6 | LEAN BEAR | -2.3 |
| GNNSF Genscript Biotech Corporation | $12B | -18.7 | 97.0 | 11.1 | -32.0 | -19.0 | 4 | BULLISH | 145.3 |
| SBHMY Sino Biopharmaceutical Limited | $14B | 35.8 | 21.1 | 40.0 | 17.7 | 28.2 | 7 | BULLISH | -19.2 |
| TEM Tempus AI, Inc. | $13B | -53.6 | -67.4 | -19.8 | 1.5 | 50.4 | 4 | BULLISH | -12.9 |
| CSPCY CSPC Pharmaceutical Group Limited | $15B | 13.0 | 25.6 | 43.2 | 32.8 | 0.7 | 6 | BULLISH | 8.3 |
| RCDTF Recordati S.p.A. | $12B | 21.6 | 24.9 | 15.4 | 16.7 | 9.2 | 7 | BULLISH | -9.2 |
| EXEL Exelixis, Inc. | $15B | 17.7 | 44.4 | 69.0 | 33.7 | 9.2 | 8 | BULLISH | 41.7 |
| CRL Charles River Laboratories International, Inc. | $14B | -60.0 | -7.7 | 6.9 | -0.1 | -0.7 | 4 | LEAN BULL | 70.2 |
| CORT Corcept Therapeutics Incorporated | $13B | 223.5 | 8.1 | 3.1 | 16.5 | 16.0 | 6 | LEAN BULL | 38.0 |
| SMMT Summit Therapeutics Inc. | $13B | -15.0 | -192.5 | 1714.4 | — | — | 3 | NEUTRAL | -18.2 |
| HALO Halozyme Therapeutics, Inc. | $13B | 31.2 | 173.7 | 32.5 | 47.8 | 41.2 | 5 | NEUTRAL | 46.6 |
| FMCQF Fresenius Medical Care AG | $12B | 11.9 | 7.3 | 7.0 | 4.5 | -0.4 | 7 | LEAN BEAR | -13.1 |
| BAX Baxter International Inc. | $12B | -11.5 | -15.7 | -1.6 | 4.3 | 5.4 | 3 | BEARISH | 0.6 |
| JAZZ Jazz Pharmaceuticals plc | $15B | 15.5 | 22.1 | 26.4 | 16.0 | 12.6 | 8 | BEARISH | 72.2 |
| ICLR ICON Public Limited Company | $12B | 37.8 | 3.5 | 5.5 | 3.5 | 2.0 | 6 | BEARISH | -15.7 |
| BBIO BridgeBio Pharma, Inc. | $13B | -18.8 | 32.4 | 57.9 | -68.4 | 193.4 | 4 | BEARISH | 25.8 |
| FMS Fresenius Medical Care AG & Co. KGaA | $12B | 11.9 | 7.3 | 6.7 | 4.5 | -0.5 | 7 | BEARISH | -16.4 |
| ASND Ascendis Pharma A/S | $14B | 16.7 | 121.1 | 76.2 | 61.0 | 114.8 | 7 | BEARISH | 11.6 |
| NBIX Neurocrine Biosciences, Inc. | $14B | 20.3 | 22.1 | 16.0 | 15.1 | 34.4 | 6 | BEARISH | 4.5 |
| JDHIY JD Health International Inc. | $15B | 15.4 | 19.1 | 49.0 | 8.4 | 31.9 | 6 | BEARISH | -49.5 |
| CLPBY Coloplast A/S | $14B | 33.6 | 18.5 | 70.9 | 19.9 | -2.9 | 5 | BEARISH | -28.4 |
| OCPNF Olympus Corporation | $13B | 27.5 | 8.7 | 11.6 | 8.4 | 1.5 | 6 | LEAN BEAR | -2.3 |
| IBRX ImmunityBio, Inc. | $11B | -10.6 | 122.7 | 33.7 | -449.6 | 192.9 | 4 | BULLISH | 314.9 |
| MRNA Moderna, Inc. | $75B | -23.8 | -39.0 | -90.1 | -539.3 | -27.2 | 2 | BULLISH | 668.3 |
| NTRA Natera, Inc. | $59B | -301.7 | -12.5 | -23.6 | -8.9 | 37.8 | 6 | BULLISH | 153.9 |
| A Agilent Technologies, Inc. | $47B | 33.0 | 21.0 | 14.9 | 19.3 | 8.6 | 7 | BULLISH | 21.0 |
| VTRS Viatris Inc. | $20B | -48.9 | -2.8 | -0.3 | -3.2 | 4.4 | 7 | BULLISH | 76.5 |
| RVTY Revvity, Inc. | $17B | 72.2 | 3.2 | 3.5 | 7.1 | 5.5 | 6 | BULLISH | 65.3 |
| GNNSF Genscript Biotech Corporation | $12B | -18.7 | 97.0 | 11.1 | -32.0 | -19.0 | 4 | BULLISH | 145.3 |
| TXG 10x Genomics, Inc. | $12B | -158.5 | -9.4 | -19.8 | -11.9 | -4.3 | 5 | BULLISH | 654.6 |
| TWST Twist Bioscience Corporation | $12B | -85.0 | -29.6 | -29.2 | -29.6 | 19.2 | 2 | BULLISH | 544.8 |
| SBHMY Sino Biopharmaceutical Limited | $14B | 35.8 | 21.1 | 40.0 | 17.7 | 28.2 | 7 | BULLISH | -19.2 |
| TMO Thermo Fisher Scientific Inc. | $242B | 35.2 | 13.5 | 8.3 | 14.5 | 7.2 | 7 | BULLISH | 23.5 |
| SRTOY Sartorius Stedim Biotech S.A. | $229B | 68.9 | 6.9 | 6.3 | 12.1 | 4.3 | 7 | BULLISH | 6.6 |
| WXXWY WuXi Biologics (Cayman) Inc. | $29B | 38.5 | 20.6 | 28.5 | 20.7 | 28.7 | 9 | BULLISH | 30.2 |
| TEM Tempus AI, Inc. | $13B | -53.6 | -67.4 | -19.8 | 1.5 | 50.4 | 4 | BULLISH | -12.9 |
| ORINY Orion Oyj | $27B | 19.4 | 53.6 | 46.3 | 26.9 | 22.6 | 7 | BULLISH | 31.4 |
| BIO-B Bio-Rad Laboratories, Inc. | $10B | 44.3 | 3.1 | 2.2 | 57.1 | 1.4 | 7 | BULLISH | 29.2 |
| DHR Danaher Corporation | $150B | 37.9 | 7.6 | 5.8 | 13.9 | 4.6 | 6 | BULLISH | 0.6 |
| RGEN Repligen Corporation | $10B | 245.5 | 2.0 | 2.6 | 2.5 | 16.5 | 8 | BULLISH | 24.6 |
| BDULF Bangkok Dusit Medical Services Public Company Limited | $10B | 19.9 | 15.0 | 12.4 | 12.1 | 1.3 | 4 | BULLISH | 3.2 |
| BTSGU BrightSpring Health Services, Inc. Tangible Equity Unit | $12B | 42.1 | 15.5 | 10.3 | 2.2 | 19.9 | 7 | BULLISH | 95.6 |
| MTD Mettler-Toledo International Inc. | $30B | 33.4 | -736.4 | 46.7 | 22.7 | 6.9 | 8 | BULLISH | 15.3 |
| CSPCY CSPC Pharmaceutical Group Limited | $15B | 13.0 | 25.6 | 43.2 | 32.8 | 0.7 | 6 | BULLISH | 8.3 |
| BRKR Bruker Corporation | $9.6B | -90.5 | -3.4 | 3.0 | -6.2 | 1.6 | 6 | BULLISH | 82.3 |
| RCDTF Recordati S.p.A. | $12B | 21.6 | 24.9 | 15.4 | 16.7 | 9.2 | 7 | BULLISH | -9.2 |
| TEVA Teva Pharmaceutical Industries Limited | $46B | 63.2 | 9.7 | 9.3 | -13.9 | 4.1 | 7 | BULLISH | 97.1 |
| WAT Waters Corporation | $42B | 105.8 | 1.9 | 1.5 | -8.3 | 52.5 | 5 | BULLISH | 33.0 |
| GH Guardant Health, Inc. | $24B | -50.9 | 171.6 | -88.3 | -35.9 | 42.7 | 6 | BULLISH | 183.8 |
| GNMSF Genmab A/S | $22B | 26.5 | 3.9 | 11.9 | 26.2 | -82.1 | 4 | BULLISH | 15.3 |
| SONVY Sonova Holding AG | $18B | 34.4 | 38.1 | 33.3 | 13.5 | 1.0 | 7 | BULLISH | 10.2 |
| UTHR United Therapeutics Corporation | $23B | 17.9 | 19.3 | 31.3 | 42.5 | 2.5 | 6 | BULLISH | 23.6 |
| SUVPF Sartorius AG | $19B | 88.8 | 7.2 | 6.7 | 7.2 | 3.4 | 8 | BULLISH | 24.7 |
| BTSG BrightSpring Health Services, Inc. Common Stock | $12B | 42.1 | 15.5 | 10.3 | 2.2 | 19.9 | 7 | BULLISH | 101.9 |
| EXEL Exelixis, Inc. | $15B | 17.7 | 44.4 | 69.0 | 33.7 | 9.2 | 8 | BULLISH | 41.7 |
| RVMDW Revolution Medicines, Inc. Warrant | $45B | -23.3 | -79.1 | 186.4 | — | — | 1 | BULLISH | 3872.4 |
| RVMD Revolution Medicines, Inc. | $44B | -23.3 | -79.1 | 186.4 | — | — | 1 | BULLISH | 350.6 |
| BMXXY bioMérieux S.A. | $11B | 19.5 | 20.5 | 18.1 | 11.5 | 45.2 | 9 | BULLISH | -38.2 |
| ISRG Intuitive Surgical, Inc. | $138B | 44.3 | 17.4 | 22.1 | 28.3 | 20.7 | 7 | BULLISH | -10.5 |
| ILMN Illumina, Inc. | $41B | 50.5 | 32.4 | 18.2 | 17.9 | 4.9 | 7 | BULLISH | 167.0 |
| ABBV AbbVie Inc. | $464B | 74.0 | -206.4 | 23.5 | 21.3 | 10.4 | 7 | BULLISH | 8.3 |
| AMGN Amgen Inc. | $218B | 24.8 | 91.5 | 19.5 | 23.6 | 9.2 | 8 | BULLISH | 36.0 |
| WILYY Demant A/S | $9.9B | 40.7 | 38.1 | 21.5 | 9.1 | 8.7 | 5 | BULLISH | 27.3 |
| IVBXF Innovent Biologics, Inc. | $22B | 116.0 | 14.2 | 93.7 | 14.5 | 115.6 | 8 | BULLISH | 4.7 |
| TKPHF Takeda Pharmaceutical Company Limited | $59B | 49.4 | 2.5 | 2.8 | 9.3 | 3.3 | 6 | BULLISH | 26.8 |
| WST West Pharmaceutical Services, Inc. | $26B | 46.4 | 19.1 | 19.0 | 17.7 | 12.4 | 9 | BULLISH | 34.6 |
| HAE Haemonetics Corporation | $4.8B | 50.8 | 12.0 | 10.4 | -5.8 | -2.0 | 6 | BULLISH | 114.5 |
| MKGAF Merck KGaA | $68B | 25.1 | 8.1 | 8.1 | 9.0 | -0.4 | 7 | LEAN BULL | 9.2 |
| LZAGY Lonza Group AG | $49B | -367.3 | 21.3 | 17.9 | 17.5 | 3.7 | 7 | LEAN BULL | -0.1 |
| MDLN Medline Inc. | $30B | 41.4 | 3.2 | 4.4 | 0.8 | — | 4 | LEAN BULL | — |
| DSKYF Daiichi Sankyo Company, Limited | $34B | 20.5 | 15.8 | 13.5 | 7.2 | 13.2 | 4 | LEAN BULL | -18.6 |
| ERFSF Eurofins Scientific SE | $15B | 25.0 | 21.7 | 11.3 | 8.2 | 9.7 | 6 | LEAN BULL | 19.6 |
| HOCPY HOYA Corporation | $52B | 30.6 | 25.7 | 51.3 | 21.9 | 10.7 | 5 | LEAN BULL | 9.7 |
| FSPKF Fisher & Paykel Healthcare Corporation Limited | $15B | 57.5 | 51.3 | 21.1 | 20.6 | 36.8 | 9 | LEAN BULL | 24.9 |
| CRL Charles River Laboratories International, Inc. | $14B | -60.0 | -7.7 | 6.9 | -0.1 | -0.7 | 4 | LEAN BULL | 70.2 |
| CSLLY CSL Limited | $118B | -23.1 | 2.8 | 26.7 | -40.2 | 10.2 | 5 | LEAN BULL | -5.4 |
| WUXIF WuXi AppTec Co., Ltd. | $80B | 22.1 | 30.2 | 35.1 | 38.9 | 24.9 | 6 | LEAN BULL | 91.1 |
| CORT Corcept Therapeutics Incorporated | $13B | 223.5 | 8.1 | 3.1 | 16.5 | 16.0 | 6 | LEAN BULL | 38.0 |
| AVTR Avantor, Inc. | $10B | -18.3 | -9.7 | -2.5 | 2.3 | -1.6 | 6 | LEAN BULL | 12.2 |
| MEDP Medpace Holdings, Inc. | $17B | 34.5 | 162.2 | 933.8 | 17.2 | 24.7 | 8 | LEAN BULL | 10.2 |
| PFE Pfizer Inc. | $158B | 36.7 | 5.0 | 12.1 | -1.6 | -0.2 | 7 | NEUTRAL | 3.9 |
| RDY Dr. Reddy's Laboratories Limited | $10B | 30.4 | 12.2 | 10.7 | 2.9 | 3.6 | 3 | NEUTRAL | -13.7 |
| TECH Bio-Techne Corporation | $11B | 61.9 | 9.0 | 8.9 | 17.0 | -0.4 | 7 | NEUTRAL | 21.0 |
| AAVXF Abivax S.A. | $10B | -17.7 | -222.4 | 781.9 | — | -70.4 | 3 | NEUTRAL | 61.4 |
| HCA HCA Healthcare, Inc. | $92B | 14.2 | -124.7 | 23.3 | 8.4 | 7.3 | 6 | NEUTRAL | 0.3 |
| SMMT Summit Therapeutics Inc. | $13B | -15.0 | -192.5 | 1714.4 | — | — | 3 | NEUTRAL | -18.2 |
| ESLOF EssilorLuxottica S.A. | $78B | 26.4 | 12.5 | 10.2 | 10.6 | 10.4 | 7 | NEUTRAL | -48.6 |
| HALO Halozyme Therapeutics, Inc. | $13B | 31.2 | 173.7 | 32.5 | 47.8 | 41.2 | 5 | NEUTRAL | 46.6 |
| SOAGY Sartorius AG ADR | $83B | 88.8 | 7.2 | 6.5 | 7.2 | 3.4 | 7 | LEAN BEAR | 10.9 |
| UHS Universal Health Services, Inc. | $11B | 7.1 | 21.0 | 12.5 | 7.7 | 10.0 | 8 | LEAN BEAR | -13.6 |
| GIKLY Grifols, S.A. | $15B | 14.2 | 8.4 | 7.4 | 8.2 | -0.2 | 6 | LEAN BEAR | -20.0 |
| MCK McKesson Corporation | $106B | 24.0 | -224.3 | 212.4 | 1.7 | 12.4 | 7 | LEAN BEAR | 18.1 |
| ONC BeOne Medicines AG | $38B | 26.4 | 14.7 | 57.2 | 13.9 | 34.3 | 8 | LEAN BEAR | 6.8 |
| BIIB Biogen Inc. | $32B | 38.7 | 4.6 | 4.8 | 3.6 | -0.5 | 3 | LEAN BEAR | 42.6 |
| TRUMY Terumo Corporation | $21B | 20.1 | 9.3 | 8.5 | 8.8 | 10.7 | 4 | LEAN BEAR | -14.0 |
| COO The Cooper Companies, Inc. | $11B | 19.4 | 6.8 | 6.3 | 40.6 | 4.7 | 6 | LEAN BEAR | -16.4 |
| DXCM DexCom, Inc. | $32B | 33.0 | 38.5 | 42.9 | 19.0 | 15.5 | 9 | LEAN BEAR | 29.2 |
| LLY Eli Lilly and Company | $1.1T | 38.2 | 102.4 | 39.2 | 30.9 | 49.6 | 9 | LEAN BEAR | 38.7 |
| HUM Humana Inc. | $47B | 36.5 | 6.8 | 17.2 | 1.7 | 18.3 | 4 | LEAN BEAR | 57.4 |
| MRK Merck & Co., Inc. | $356B | 114.5 | 7.0 | 6.1 | -8.0 | 4.5 | 4 | LEAN BEAR | 61.5 |
| FMCQF Fresenius Medical Care AG | $12B | 11.9 | 7.3 | 7.0 | 4.5 | -0.4 | 7 | LEAN BEAR | -13.1 |
| SAUHF Straumann Holding AG | $18B | 38.5 | 36.0 | 38.6 | 18.2 | 7.9 | 6 | LEAN BEAR | 3.4 |
| GMED Globus Medical, Inc. | $10B | 19.0 | 11.8 | 12.3 | 19.2 | 19.7 | 8 | BEARISH | 28.8 |
| HLNCF Haleon plc | $39B | 18.1 | 9.4 | 7.3 | 14.7 | -2.1 | 7 | BEARISH | 2.1 |
| RSMDF ResMed Inc. | $44B | 21.0 | 24.3 | 25.3 | 26.2 | 9.9 | 7 | BEARISH | -14.5 |
| SDZNY Sandoz Group AG | $36B | 55.5 | 9.3 | 17.9 | 1.9 | 134.6 | 5 | BEARISH | 47.5 |
| ALPMF Astellas Pharma Inc. | $26B | 11.0 | 17.5 | 14.8 | 8.1 | 12.5 | 8 | BEARISH | 29.5 |
| IDXX IDEXX Laboratories, Inc. | $41B | 36.4 | 74.2 | 46.5 | 27.8 | 12.8 | 9 | BEARISH | -16.4 |
| SGIOY Shionogi & Co., Ltd. | $15B | 9.0 | 13.6 | 9.9 | 50.6 | 10.3 | 5 | BEARISH | 1.5 |
| BAX Baxter International Inc. | $12B | -11.5 | -15.7 | -1.6 | 4.3 | 5.4 | 3 | BEARISH | 0.6 |
| DVA DaVita Inc. | $11B | 15.4 | -149.4 | 17.9 | 7.5 | 6.4 | 8 | BEARISH | 34.5 |
| GKOS Glaukos Corporation | $9.7B | -50.4 | -26.0 | -12.7 | -9.9 | 41.5 | 3 | BEARISH | 96.9 |
| GNGBY Getinge AB (publ) | $6.7B | 25.1 | 8.9 | 8.0 | 10.0 | -3.9 | 8 | BEARISH | 11.1 |
| BAYRY Bayer AG | $50B | -25.5 | -5.5 | 6.4 | 2.0 | -1.5 | 4 | BEARISH | 45.3 |
| SEMHF Siemens Healthineers AG | $49B | 19.1 | 12.1 | 8.4 | 11.6 | 10.0 | 9 | BEARISH | -21.2 |
| JAZZ Jazz Pharmaceuticals plc | $15B | 15.5 | 22.1 | 26.4 | 16.0 | 12.6 | 8 | BEARISH | 72.2 |
| GILD Gilead Sciences, Inc. | $179B | -55.7 | -20.6 | -3.4 | -134.5 | 5.5 | 5 | BEARISH | 31.1 |
| IQV IQVIA Holdings Inc. | $42B | 31.8 | 23.0 | 9.6 | 5.9 | 8.2 | 7 | BEARISH | 26.7 |
| IPSEY Ipsen S.A. | $55B | 22.5 | 21.9 | 29.9 | 17.5 | 22.1 | 6 | BEARISH | 26.2 |
| CAH Cardinal Health, Inc. | $53B | 31.4 | -60.5 | 92.8 | 0.6 | 14.2 | 8 | BEARISH | 44.5 |
| UCBJF UCB S.A. | $45B | 17.7 | 34.2 | 26.5 | 26.0 | 44.5 | 8 | BEARISH | -18.9 |
| GEHC GE HealthCare Technologies Inc. | $29B | 18.5 | 15.4 | 10.6 | 10.8 | 1.4 | 5 | BEARISH | -14.8 |
| EW Edwards Lifesciences Corporation | $49B | 48.9 | 9.5 | 17.9 | 13.9 | 14.6 | 6 | BEARISH | 11.6 |
| BNTX BioNTech SE | $24B | -12.7 | -9.3 | -18.0 | -777.3 | -8.2 | 2 | BEARISH | -5.2 |
| SOLV Solventum Corporation | $15B | 10.7 | 34.0 | 18.1 | 4.2 | -0.9 | 7 | BEARISH | 20.3 |
| ICLR ICON Public Limited Company | $12B | 37.8 | 3.5 | 5.5 | 3.5 | 2.0 | 6 | BEARISH | -15.7 |
| BBIO BridgeBio Pharma, Inc. | $13B | -18.8 | 32.4 | 57.9 | -68.4 | 193.4 | 4 | BEARISH | 25.8 |
| DGX Quest Diagnostics Incorporated | $26B | 24.4 | 14.4 | 9.5 | 10.5 | 9.9 | 8 | BEARISH | 28.7 |
| RPRX Royalty Pharma plc | $25B | 23.7 | 12.4 | 10.6 | 2.7 | 10.0 | 6 | BEARISH | 58.2 |
| THC Tenet Healthcare Corporation | $21B | 9.9 | 53.3 | 19.1 | 14.7 | 5.4 | 7 | BEARISH | 28.4 |
| FMS Fresenius Medical Care AG & Co. KGaA | $12B | 11.9 | 7.3 | 6.7 | 4.5 | -0.5 | 7 | BEARISH | -16.4 |
| PODD Insulet Corp. | $9.1B | 24.6 | 26.0 | 21.3 | 11.8 | 29.4 | 9 | BEARISH | -57.0 |
| RHHBF Roche Holding AG | $335B | 22.5 | 58.7 | 38.1 | 22.6 | 1.8 | 5 | BEARISH | 11.7 |
| ROIV Roivant Sciences Ltd. | $26B | -94.0 | -6.2 | -217.5 | -13164.4 | -67.6 | 1 | BEARISH | 126.8 |
| EHC Encompass Health Corporation | $12B | 19.3 | 25.5 | 16.7 | 9.6 | 9.5 | 9 | BEARISH | -3.8 |
| JNJ Johnson & Johnson | $617B | 29.6 | 25.7 | 19.4 | 21.9 | 8.1 | 7 | BEARISH | 38.5 |
| FSNUY Fresenius SE & Co. KGaA | $112B | 15.9 | 8.1 | 5.6 | 6.4 | 5.9 | 7 | BEARISH | -11.5 |
| ELV Elevance Health Inc. | $84B | 17.2 | 11.2 | 15.5 | 2.9 | 6.3 | 6 | BEARISH | 16.8 |
| REGN Regeneron Pharmaceuticals, Inc. | $76B | 17.6 | 14.0 | 12.9 | 30.2 | 9.3 | 7 | BEARISH | 22.7 |
| CNC Centene Corp. | $31B | -6.1 | -20.4 | -37.1 | 2.5 | 8.7 | 6 | BEARISH | 76.2 |
| LH Labcorp Holdings Inc. | $25B | 25.3 | 11.7 | 8.6 | 8.0 | 6.4 | 8 | BEARISH | 10.9 |
| UNH UnitedHealth Group Incorporated | $338B | 23.9 | 14.6 | 13.2 | 4.9 | 6.5 | 7 | BEARISH | 7.5 |
| NBIX Neurocrine Biosciences, Inc. | $14B | 20.3 | 22.1 | 16.0 | 15.1 | 34.4 | 6 | BEARISH | 4.5 |
| ASND Ascendis Pharma A/S | $14B | 16.7 | 121.1 | 76.2 | 61.0 | 114.8 | 7 | BEARISH | 11.6 |
| NVS Novartis AG | $268B | 21.3 | 30.6 | 16.8 | 22.7 | 0.8 | 5 | BEARISH | 7.0 |
| SYK Stryker Corporation | $106B | 28.3 | 16.5 | 11.6 | 19.4 | 8.5 | 9 | BEARISH | -24.4 |
| COR Cencora, Inc. | $60B | 22.9 | 104.3 | 26.5 | 0.9 | 5.1 | 7 | BEARISH | -0.7 |
| VRTX Vertex Pharmaceuticals Incorporated | $128B | 29.1 | 23.5 | 28.3 | 33.0 | 10.6 | 6 | BEARISH | 24.8 |
| BMY Bristol-Myers Squibb Company | $125B | 13.5 | 46.7 | 17.9 | 25.6 | 3.1 | 8 | BEARISH | 30.7 |
| MDT Medtronic plc | $111B | 21.1 | 9.8 | 7.5 | 12.7 | 8.4 | 8 | BEARISH | -8.9 |
| BDX Becton, Dickinson and Company | $49B | 53.3 | 3.8 | 4.1 | 7.6 | -2.6 | 6 | BEARISH | -6.9 |
| INCY Incyte Corporation | $23B | 14.2 | 30.7 | 82.1 | 35.0 | 26.9 | 8 | BEARISH | 33.0 |
| ZBH Zimmer Biomet Holdings, Inc. | $17B | 21.4 | 6.4 | 5.9 | 9.1 | 8.6 | 6 | BEARISH | -10.7 |
| MDGL Madrigal Pharmaceuticals, Inc. | $12B | -38.7 | -53.3 | -778.9 | -15.9 | 149.0 | 2 | BEARISH | 11.2 |
| ABT Abbott Laboratories | $169B | 31.4 | 10.7 | 7.3 | 7.4 | 8.1 | 5 | BEARISH | -26.6 |
| CVS CVS Health Corp. | $110B | 22.6 | 6.2 | 4.9 | 2.8 | 7.4 | 8 | BEARISH | 13.4 |
| ARGNF argenx SE | $58B | 33.3 | 44.4 | 70.5 | 29.8 | 225.2 | 6 | BEARISH | 17.0 |
| OTSKF Otsuka Holdings Co., Ltd. | $38B | 14.7 | 13.7 | 12.0 | 16.7 | 9.5 | 8 | BEARISH | 27.5 |
| IHHHF IHH Healthcare Berhad | $15B | 30.7 | 7.3 | 6.1 | 8.1 | 7.1 | 5 | BEARISH | 49.1 |
| BIOVF Swedish Orphan Biovitrum AB (publ) | $15B | 107.8 | 3.4 | 17.2 | 14.0 | 13.3 | 4 | BEARISH | 42.8 |
| PMCUF Pro Medicus Limited | $11B | 61.6 | 119.2 | 123.5 | 68.7 | 65.7 | 5 | BEARISH | -46.2 |
| BMRN BioMarin Pharmaceutical Inc. | $11B | 150.5 | 1.2 | 1.4 | 4.5 | 11.2 | 4 | BEARISH | 4.2 |
| AZN AstraZeneca PLC | $243B | 23.4 | 22.0 | 15.0 | 16.3 | 8.6 | 9 | BEARISH | -2.8 |
| INSM Insmed Incorporated | $24B | -27.0 | -87.2 | -364.8 | -3.1 | 185.8 | 5 | BEARISH | -24.6 |
| STE STERIS plc | $20B | 25.4 | 11.3 | 9.4 | 13.9 | 8.7 | 9 | BEARISH | -13.4 |
| JDHIY JD Health International Inc. | $15B | 15.4 | 19.1 | 49.0 | 8.4 | 31.9 | 6 | BEARISH | -49.5 |
| ALGN Align Technology, Inc. | $10B | 25.0 | 10.2 | 12.3 | 10.3 | 4.4 | 7 | BEARISH | 12.7 |
| CHEOF Cochlear Limited | $6.1B | 55.7 | 30.0 | 34.3 | -1.2 | 11.5 | 6 | BEARISH | -47.4 |
| NVO Novo Nordisk A/S | $166B | 9.5 | 59.8 | 35.2 | 26.7 | 5.6 | 5 | BEARISH | -37.0 |
| SNY Sanofi | $96B | 21.7 | 5.7 | 6.4 | 2.8 | 13.4 | 6 | BEARISH | -19.8 |
| GSK GSK plc | $94B | 14.8 | 25.5 | 18.8 | 5.2 | 5.0 | 7 | BEARISH | 4.3 |
| CI Cigna Corporation | $71B | 11.2 | 15.5 | 11.8 | 2.3 | 7.7 | 8 | BEARISH | -6.7 |
| BSX Boston Scientific Corporation | $63B | 17.2 | 15.5 | 11.6 | 16.7 | 13.5 | 8 | BEARISH | -55.6 |
| CHGCF Chugai Pharmaceutical Co., Ltd. | $63B | 21.1 | 23.7 | 45.1 | 34.1 | 12.6 | 6 | BEARISH | -13.9 |
| ALC Alcon Inc. | $31B | 49.0 | 2.9 | 3.6 | 0.0 | 7.8 | 6 | BEARISH | -15.1 |
| ALNY Alnylam Pharmaceuticals, Inc. | $29B | 36.0 | 100.7 | -152.8 | 12.7 | 95.1 | 6 | BEARISH | -52.3 |
| ZTS Zoetis Inc. | $29B | 11.5 | 64.4 | 26.3 | 28.0 | 1.4 | 6 | BEARISH | -52.4 |
| PHG Koninklijke Philips N.V. | $23B | 18.2 | 10.2 | 7.6 | 8.8 | -1.1 | 6 | BEARISH | -13.4 |
| CLPBY Coloplast A/S | $14B | 33.6 | 18.5 | 70.9 | 19.9 | -2.9 | 5 | BEARISH | -28.4 |
| PEN Penumbra, Inc. | $13B | 77.6 | 11.4 | 13.6 | 8.9 | 17.6 | 6 | BEARISH | 27.2 |
| SNN Smith & Nephew plc | $11B | 17.2 | 21.7 | 17.4 | 9.8 | 11.5 | 8 | BEARISH | -27.6 |
| ELAN Elanco Animal Health Incorporated | $11B | -54.0 | -3.0 | 3.7 | 3.9 | 12.0 | 5 | BEARISH | 6.5 |
| ENSG The Ensign Group, Inc. | $10B | 26.1 | 17.0 | 8.1 | 6.9 | 18.9 | 7 | BEARISH | -1.5 |
Profile Radar
Valuation vs Profitability
Performance Comparison
Industry Market Share
OCPNF vs Benchmarks
ROIC
Gross Margin
Op Margin
Net Margin
Revenue Growth
P/E Ratio
ROE
Piotroski F